XJSE
ASC
Market cap27mUSD
Nov 28, Last price
92.00ZAR
Name
Ascendis Health Ltd
Chart & Performance
P/E
39.76
P/S
—
EPS
0.02
Div Yield, %
—
Shrs. gr., 5y
5.31%
Rev. gr., 5y
-23.38%
Revenues
0k
-100.00%
Net income
11m
-80.32%
CFO
-12m
L+51.02%
Dividend
May 10, 201711 ZAR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ascendis Health Limited is a health and wellness enterprise that manufactures and distributes healthcare products across South Africa, Cyprus, Spain, Hungary, Romania, and other international markets. The company's operations are divided into three key segments: Consumer Health, Pharma, and Medical. Within its Consumer Health portfolio, it offers a variety of body and skin care items, alongside numerous supplements such as natural, multi-vitamin, mineral, micronutrient, and nutraceutical options, as well as homeopathic and herbal remedies, marketed under brands like Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce. The Medical segment provides essential medical devices, diagnostic laboratory equipment, and related consumables for diverse settings, including operating theatres, ICUs, trauma units, maternity and general wards, radiology, pathology labs, and scientific research institutes. Concurrently, the Pharma division offers a wide array of generic pharmaceutical products, encompassing antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives, and treatments targeting the nervous and cardiovascular systems, dermatological issues, and antimalarial conditions, among other therapeutic solutions. These medical and pharmaceutical products are distributed under brands such as Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, and The Scientific Group. Ascendis Health also exports its products and serves a broad customer base including pharmacies, retailers, beauticians, and doctors. The company was founded in 2008 and is headquartered in Johannesburg, South Africa.
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||